Clinical trials: Von Willebrand Disease (vWD)
Von Willebrand Disease, Type 1
Evaluation of Bleeding Score in Egyptian Patients With vWD Type I and Correlate it With Laboratory Parameters
Applying the ISTH-BAT questionnaire on Egyptian patients with type I VWD aiming to correlate the BS with the laboratory findings
- Trial name
- NCT03915873
- Testing
- The von Willebrand Antigen level
- Volunteers
- 20 people
- Sponsor
- Assiut University
Von Willebrand Disease (VWD)
A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
The main aim of the study is to check effectiveness of rVWF (vonicog alfa) prophylaxis based on the annualized bleeding rate (ABR) of spontaneous (not related to trauma) bleeding episodes in pediatric and adult participants…
- Trial name
- NCT03879135
- Testing
- rVWF, rFVIII
- Where
- 33 sites in United States, Austria and 7 more
- Volunteers
- 38 people
- Sponsor
- Baxalta now part of Shire
Von Willebrand Disease
Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)
The purpose of this Phase 3 study is to assess the pharmacokinetics of rVWF:rFVIII and rVWF, and to assess the safety and efficacy of rVWF:rFVIII and rVWF in the treatment of bleeding events in subjects with severe hereditary von…
- Trial name
- NCT01410227
- Testing
- Recombinant von Willebrand factor (rVWF), Recombinant factor VIIII (rFVIII)
- Where
- 52 sites in United States, Australia and 14 more
- Volunteers
- 49 people
- Sponsor
- Baxalta now part of Shire
Antiplatelet Therapy, Healthy Donors
T-TAS® wS Method Comparison
This study involves the collection of blood samples and measurement with the T-TAS PL assay to compare the performance of the T-TAS wS instrument to the T-TAS 01 instrument
- Conditions
- Antiplatelet Therapy, Healthy Donors, Von Willebrand Disease (VWD)
- Trial name
- NCT06710262
- Testing
- T-TAS PL Assay
- Where
- 2 sites in United States
- Volunteers
- 115 people
- Sponsor
- Hikari Dx, Inc.
Von Willebrand Disease (VWD)
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
The main aim of this study is to find out if VONVENDI is safe for adult Chinese participants with VWD. The study will also check how well VONVENDI helps control bleeding with or without product ADVATE in the participants who may…
- Trial name
- NCT07129343
- Testing
- VONVENDI, ADVATE
- Where
- 7 sites in China
- Volunteers
- 20 people
- Sponsor
- Takeda
VWD - Von Willebrand's Disease
Effectiveness and Tolerability of Eqwilate in Real-life Conditions
MOdalities of use, effectiveNEss and TOlerability of Eqwilate® a balanced combInatiON of VWF and FVIII in von WillEbrand patients in real-life conditions: the ONE-TO-ONE study
- Trial name
- NCT04106908
- Testing
- Eqwilate
- Where
- 9 sites in France
- Volunteers
- 38 people
- Sponsor
- Octapharma
Von Willebrand Disease
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
Description of the long-term evolution of patients with von Willebrand disease and treated with Voncento® and of the hemostatic efficacy in the prevention and the treatment of non-surgical bleeding episodes and prevention of…
- Trial name
- OPALE (NCT04657887)
- Testing
- Voncento®
- Where
- 17 sites in France
- Volunteers
- 135 people
- Sponsor
- CSL Behring
Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
This is a first-in-human (FIH), Phase 1/2, 3-part open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy study evaluating HMB-002 in participants with VWD.
- Conditions
- Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
- Trial name
- NCT06754852
- Testing
- HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 108 people
- Sponsor
- Hemab ApS
Von Willebrand Disease (VWD), Acquired Von Willebrand Disease
Endothelial Colony-Forming Cells in Patients With VWD, AVWS and Healthy Subjects
The goal of this observational study is to learn how endothelial colony-forming cells (ECFCs) behave in people with von Willebrand disease (VWD), acquired von Willebrand syndrome (AVWS), and in healthy individuals.
- Trial name
- ECFCs/2022 (NCT07358013)
- Testing
- Blood sample collection for VWF measurements in plasma, Blood sample collection for ECFC isolation and characterization, Genetic testing of VWF
- Where
- Italy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Von Willebrand Disease (VWD), Inherited Bleeding Disorders in Children
Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate
Von Willebrand disease (VWD) is the most common inherited bleeding disorder in children. It occurs due to a deficiency or dysfunction of von Willebrand factor, a protein that plays an essential role in blood clotting.
- Conditions
- Von Willebrand Disease (VWD), Inherited Bleeding Disorders in Children, Pediatric Hemostatic Disorders
- Trial name
- VWD-ASSIUT (NCT07410130)
- Testing
- Tranexamic Acid, Von Willebrand Factor-Containing Concentrates
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Assiut University
Von Willebrand Disease (VWD)
A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers
The main aim of this study is to describe the experience and unmet needs of persons living with VWD and their caregivers in Canada.
- Trial name
- NCT05695560
- Testing
- No Intervention
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Takeda
Cerebral Microbleeds, Congenital Haemophilia, Congenital Von Willebrand Disease
Severe Congenital Hemostatic Defects, Cerebral MIcrobleeds and COGnition
Cerebral microbleeds (CMBs) are haemosiderin deposits, resulting from the leakage of erythrocytes from small cerebral vessels, which can be detected noninvasively using susceptibility-sensitive magnetic resonance imaging (MRI)…
- Trial name
- HEMICOG (NCT06090201)
- Testing
- 3-Tesla brain MRI and a comprehensive neuropsychological assessment
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Lille
Von Willebrand Diseases
A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD
The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy…
- Trial name
- EMPOWER (NCT06205095)
- Testing
- Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Unity Health Toronto
Von Willebrand Diseases
Minimize Menorrhagia in Women With Von Willebrand Disease
This is an outpatient, 24-week Phase III prospective, randomized, crossover trial comparing recombinant von Willebrand factor (rVWF) and tranexamic acid (TA, Lysteda®) to minimize menorrhagia in women with von Willebrand disease…
- Trial name
- VWDMin (NCT02606045)
- Testing
- recombinant von Willebrand factor, tranexamic acid
- Where
- 19 sites in United States
- Volunteers
- 39 people
- Sponsor
- Margaret Ragni
Von Willebrand Disease (VWD)
A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi
The main aim of this study is to estimate the risks of certain adverse events in adults with Von Willebrand Disease treated with VEYVONDI. No study medicines will be provided to participants in this study.
- Trial name
- NCT05265078
- Where
- Germany
- Volunteers
- 102 people
- Sponsor
- Takeda
Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
- Trial name
- HMBeacon (NCT07575308)
- Testing
- ALN-6400
- Where
- 21 sites in United States, Netherlands and 3 more
- Volunteers
- 24 people
- Sponsor
- Alnylam Pharmaceuticals
VWD - Von Willebrand's Disease
The Severe Von Willebrand Disease (sVWD) Patient Registry
A web-based registry will be created by the sponsor, VWD Connect Foundation (VCF), to collect data on patients with severe Von Willebrand Disease (sVWD).
- Trial name
- NCT05437536
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- VWD Connect Foundation
Von Willebrand Disease (vWD)
An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)
This study is conducted in Japan of vonicog alfa (rVWF) used to treat pediatric participants with Von Willebrand Disease (vWD). The main aim of the study is to evaluate adverse drug reaction and effectiveness of vonicog alfa…
- Trial name
- NCT07404644
- Testing
- vonicog alfa (rVWF)
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Takeda
Von Willebrand Disease (VWD)
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
- Trial name
- VIVID-6 (NCT07115004)
- Testing
- VGA039
- Where
- 32 sites in United States, Australia and 8 more
- Volunteers
- 60 people
- Sponsor
- Vega Therapeutics, Inc
Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous bleeding, HMB, surgical bleeding or other hemostatic challenges.
- Trial name
- BCDI-XII (NCT05500807)
- Testing
- Emicizumab
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bleeding and Clotting Disorders Institute Peoria, Illinois